Nanobodies: an unexplored opportunity to combat COVID-19

Ezzikouri, Sayeh; Nourlil, Jalal; Tsukiyama-Kohara, Kyoko; Kohara, Michinori; Ossmani, Hicham El; Windisch, Marc P.

doi:10.1080/07391102.2020.1845801

Cited by 11 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vobarilizumab (ALX-0061) is a bispecific nanobody against albumin and IL-6R and has been used for the treatment of moderate to severe RA in a phase 2b clinical trial (166) and further evaluation of its efficacy against systemic lupus erythematosus (SLE) is under investigation [167] , [168] , [169] , [170] . It has 10 times more than TCZ and has 2000 times more affinity than TCZ to the receptor.…”

Section: Filgotinibmentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

Section: Filgotinibmentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…COVID-19 is a highly contagious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) ( Ezzikouri et al, 2020 ). Vaccines are effective preventive strategies to prevent COVID-19.…”

Section: Introductionmentioning

confidence: 99%

A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals

Yang

Zhao

et al. 2022

Research in Veterinary Science

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARSCoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.

show abstract

“…The first adult medication developed based on the single-domain antibody (sdAb) was approved in November 2018 by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) [ 38 , 41 ]. The antiviral effects of nanobodies against respiratory viruses such as coronavirus have been demonstrated in a host of investigations [ 42 ]. The SARS-CoV-2 spike protein has been used to immunize some animals and discover nanobodies that interact with the virus's receptor-binding region [ 43 ].…”

Section: What Are Nanobodiesmentioning

confidence: 99%

The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization

et al. 2021

View full text Add to dashboard Cite

The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.

show abstract

Nanobodies: an unexplored opportunity to combat COVID-19

Cited by 11 publications

References 19 publications

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals

The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization

Contact Info

Product

Resources

About